Inclusion Criteria:

- Women 21-70 years old (Women over 70 are offered chemotherapy less frequently because
of their risk benefit ratio. Including them would be a selection bias because of
their differential underexposure).

- Initiated taxane-based chemotherapy in the neoadjuvant, adjuvant, or previously
untreated metastatic setting.

- The range of exposure to taxane-based chemotherapy will include women on active
treatment having received two cycles, to women who are within three months of their
last infusion.

- Documented symptoms of CIPN per CTCAE grading criteria (half of sample) or NO
symptoms (half of sample) Grade 0 = no CIPN symptoms Grade 1 = mild symptoms Grade 2
= moderate symptoms - prescribed Gabapentin (Neurontin) Grade 3&4= severe symptoms -
treated with Gabapentin (Neurontin), treatment plan altered

Exclusion Criteria:

- Physical disabilities - defined by use of assistive devices to complete functional
tasks (wheelchair, crutches, prosthetic limbs) prior to starting chemotherapy.

- Current exposure to neurotoxic agents (Navelbine, platinums or other taxanes)

- Pregnancy during chemotherapy treatment

- Diabetes - diagnosed 3 or more years , or insulin dependent, or with clinically
established neuropathy

- Previous exposure to chemotherapy or radiotherapy

- HIV positive (high risk for neuropathy)

- Other neurological diseases, such as Multiple Sclerosis

- Other pre-existing neuropathy